Premium
Diversity‐Oriented Synthesis of Diol‐Based Peptidomimetics as Potential HIV Protease Inhibitors and Antitumor Agents
Author(s) -
Vadhadiya Paresh M.,
Jean MarcAlexandre,
Bouzriba Chahrazed,
Tremblay Thomas,
Lagüe Patrick,
Fortin Sébastien,
Boukouvalas John,
Giguère Denis
Publication year - 2018
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.201800247
Subject(s) - peptidomimetic , protease , hiv 1 protease , docking (animal) , chemistry , combinatorial chemistry , human immunodeficiency virus (hiv) , stereochemistry , diol , enzyme , biochemistry , biology , virology , organic chemistry , medicine , peptide , nursing
Peptidomimetic HIV protease inhibitors are an important class of drugs used in the treatment of AIDS. The synthesis of a new type of diol‐based peptidomimetics is described. Our route is flexible, uses d ‐glucal as an inexpensive starting material, and makes minimal use of protection/deprotection cycles. Binding affinities from molecular docking simulations suggest that these compounds are potential inhibitors of HIV protease. Moreover, the antiproliferative activities of compounds 33 a , 35 a , and 35 b on HT‐29, M21, and MCF7 cancer cell lines are in the low micromolar range. The results provide a platform that could facilitate the development of medically relevant asymmetrical diol‐based peptidomimetics.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom